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 Abstract 27 
 28 
One of the greatest challenges currently faced in tissue engineering is the 29 
incorporation of vascular networks within tissue-engineered constructs. The aim of 30 
this study was to develop a technique for producing a perfusable, three-dimensional 31 
cell friendly model of vascular structures that could be used to study the factors 32 
affecting angiogenesis and vascular biology in engineered systems in more detail.  33 
Initially, biodegradable synthetic pseudo-vascular networks were produced via the 34 
combination of robocasting and electrospinning techniques. The internal surfaces of 35 
the vascular channels were then recellularized with human dermal microvascular 36 
endothelial cells (HDMECs) with and without the presence of human dermal 37 
fibroblasts (HDFs) on the outer surface of the scaffold. After 7 days in culture, 38 
channels that had been reseeded with HDMECs alone, demonstrated irregular cell 39 
coverage. However when using a co-culture of HDMECs inside and HDFs outside the 40 
vascular channels, coverage was found to be continuous throughout the internal 41 
channel. Using this cell combination, collagen gels loaded with vascular endothelial 42 
growth factor were deposited onto the outer surface of the scaffold and cultured for a 43 
further 7 days after which endothelial cell (EC) outgrowth from within the channels 44 
into the collagen gel was observed showing the engineered vasculature maintains its 45 
capacity for angiogenesis. Furthermore the HDMECs appeared to have formed 46 
perfusable tubules within the gel. These results show promising steps towards the 47 
development of an in vitro platform upon which to study angiogenesis and vascular 48 
biology in a tissue-engineering context. 49 
50 
 Introduction 51 
There has been significant progress in the field of tissue engineering over recent 52 
years, however one of the current obstacles blocking major clinical translation is the 53 
production of thick (≥2 mm), complex tissues due to the lack of rapid 54 
neovascularization of the constructs [Griffith et al., 2005].  Blood vessel formation is 55 
tightly regulated and relies on the chronologically precise adjustment of vessel 56 
growth, maturation and suppression of EC growth - all of which are controlled by a 57 
large number of factors that influence each other [Carmeliet and Jain, 2011]. To 58 
induce vascularization within tissue engineered (TE) substitutes these same processes 59 
need to occur and it is therefore not surprising that this remains a challenge in the 60 
tissue-engineering field.  61 
The most promising approaches to circumvent slow revascularization of tissue 62 
engineered constructs have historically used the body as an in vivo bioreactor making 63 
use of the omentum and in some case arteriovenous shunts. For example Baumert et 64 
al 2007 and Saxena et al, 2010  used the omentum and the body as an in vivo 65 
bioreactor for tissue engineering of bladder and cardiac tissue respectively.  Baumert 66 
et al used pig urothelial and smooth muscle cells  seeded into sphere shaped small 67 
intestinal submucosa (SIS) matrix grafts and after 3 weeks, transferred into the 68 
omentum in the pig.  Three weeks later at harvest, these were found to be highly 69 
vascularised and the authors concluded that the omentum permitted the in vivo 70 
maturation of these seeded scaffolds with the development of a dense vasculature 71 
which they anticipate to prevent fibrosis and loss of contractility. Saxena et al 72 
implanted their tissue engineered constructs - ovine oesophageal epithelial cells 73 
implanted on collagen sheets pre-seeded with fibroblasts to form a rudimentary 74 
 tubularised oesophagus into the sheep omentum and demonstrated vascular coverage 75 
and ingrowth into the periphery of the construct.  76 
 77 
An alternative approach is that of using an arteriovenous shunt.  Burla et al 2005 78 
achieved vascularisation for neonatal cardiac myocytes placed in silicone chambers 79 
close to a vascular pedicle.  In 2006 Kneser et al used an arteriovenous loop in a rat 80 
model to overcome the problem of engineering larger volume bone tissues. This  81 
approach of using an AV shunt  was considered in a review of the challenges of 82 
angiogenesis and tissue engineering by Laschke et al 2006.  These authors concluded 83 
however that future directions should focus on the creation of microvascular networks 84 
within 3D tissue constructs in vitro prior to implantation. We have also recently 85 
reviewed this area (Dew et al., 2015 and conclude that progress remains  slow in 86 
neovascularisation of tissue engineered constructs because there are very few systems 87 
which allow one to study  perfusion conditions, the cell type and scaffold architecture 88 
Ð all of which are important for  neovascularization. We suggest it is therefore 89 
important to take a step back and understand how these factors work together to 90 
promote angiogenesis in order to advance this crucial area. 91 
Clinically  the study of angiogenesis has increased rapidly over the last 40 years as a 92 
result of its major role in  a number of pathologies including cancer, rheumatoid 93 
arthritis and retinopathies to name but a few [Carmeliet, 2000]. Assays have been 94 
developed in an attempt to study the process. Ideally these would enable the 95 
assessment of multiple factors, providing reliable and reproducible results directly 96 
relating to those found in the clinic [Staton et al., 2009]. From the observations 97 
gleaned from tissue engineering strategies this would include the combination of a 98 
relevant vascular architecture, the ability to incorporate the relevant cell combinations 99 
 along with flow conditions and appropriate extracellular matrix (ECM) components. 100 
There is currently no single Ôgold standard' assay that provides a useful platform to 101 
incorporate all of these elements in an in vitro setting. 102 
We have developed a novel 4-step technique to produce an in vitro angiogenesis 103 
model via the combination of electrospinning and robocasting methods used widely in 104 
the tissue-engineering field [Ortega et al., 2015].  Using the combination of these two 105 
approaches offers a range of advantages in the design of angiogenesis assays. For 106 
instance, the use of robocasting allows for the tuning of the vascular network 107 
geometry in terms of size, thickness and morphology enabling bespoke designs to be 108 
tested rapidly and scaled-up easily where necessary. The use of electrospun fibres 109 
provides high levels of porosity and surface area to enable diffusion and facilitate cell 110 
attachment, respectively [Ashammakhi et al., 2008]. In addition electrospinning also 111 
offers the ability to easily spin different polymers allowing for the control of 112 
degradation times [Blackwood et al., 2008] and mechanical properties whilst enabling 113 
the combination of different membrane combinations, as recently reported by our 114 
group [Bye et al., 2013].  Synthetic pseudovascular networks produced via this 115 
methodology provide a surface that supports EC adhesion [Ellis-Behnke et al., 2006; 116 
Beachley and Wen, 2010; Bye et al., 2013] and could provide the ability to test a 117 
range of angiogenic growth factors, combine multiple cell combinations and study the 118 
effects of perfusion through interconnected afferent and efferent channels. In this 119 
study we firstly describe the recellularization of such scaffolds using both HDMECs 120 
and HDFs in different combinations. We then describe the use of these scaffolds to 121 
observe the outgrowth of 3D tubular structures into a Vascular Endothelial Growth 122 
Factor (VEGF) loaded collagen gel.  123 
 124 
  125 
Materials and Methods 126 
Production of synthetic pseudovascular nets. Synthetic pseudovascular nets were 127 
produced using a 4 step technique using a combination of electrospinning and 128 
robocasting as previously published [Ortega et al., 2015]. Briefly, electrospun mats 129 
were produced by dissolving medical grade poly(3-hydroxybutyrate-co-3-130 
hydroxyvalerate) (PHBV; Goodfellow) in a mixture of dichloromethane (DCM) and 131 
methanol. An optimal concentration of 10% w//w of PHBV (containing 10% w//w of 132 
methanol) was prepared and electrospun. Alginate was robocast onto the PHBV 133 
electrospun mat with the purpose of acting as a sacrificial template. An alginate paste 134 
was placed inside a syringe barrel attached to a dispensing system (Ultra 2800, EFD 135 
Inc., East Province, USA) whilst a 3D printer (RepRap Mendel, Oldbury on Severn, 136 
UK) was used to hold the dispensing arm and print the alginate. The electrospinning 137 
process was then repeated to cover the alginate sacrificial template with a nanofibrous 138 
PHBV layer. To remove the alginate and achieve the creation of a hollow network 139 
between the two electrospun mats, the scaffolds were submerged in 0.5 M 140 
ethylenediaminetetraacetic acid (EDTA) solution overnight on a gel-shaker set to 70 141 
rpm. 142 
The overall dimensions of these nets as shown in Fig 1 were 2x4cm with tubes that 143 
were approximately 0.5 mm wide with a flat bottom and curved ceiling with a height 144 
of 0.15 mm (please see [Ortega et al., 2015] for detailed structures).  The hexagonal 145 
section of the scaffold measured approximately 5x7.5mm at the widest points. 146 
 147 
Cells and cell culture Proliferating HDMECs from juvenile foreskin (Promocell, 148 
Heidelberg, Germany) were grown in gelatin coated (0.1% (w/v) pig skin gelatin in 149 
 PBS) T25 tissue culture flasks. Cells were grown in EC growth medium MV 150 
containing 0.05ml/ml FCS, 0.004 ml/ml EC growth supplement, 10ng/ml epidermal 151 
growth factor (recombinant human), 90 µg/ml heparin, 1 µg/ml hydrocortisone, 100 152 
U/ml penicillin, 0.1 mg/ml streptomycin and 0.25 µg/ml amphotericin B. Media was 153 
replenished every 2-3 days. HDMECs were passaged when they reached 154 
approximately 80% confluence, split using a ratio of 1:3 and were used at passage 5 155 
in this study.  HDFs were cultured from skin samples taken from consenting patients 156 
undergoing elective abdominoplasty or breast reduction surgery, as described 157 
previously [Bye et al., 2014] and used under the requirements stipulated by Research 158 
Tissue Bank Licence 12179. HDFs were cultured in DMEM supplemented with FCS 159 
(10% v/v), streptomycin (0.1 mg/ml), penicillin (100 IU/ml) and amphotericin B (0.5 160 
g/ml) and used between passage 6-8. 161 
 162 
Endothelialization of synthetic pseudovascular nets. Prior to cell culture, scaffolds 163 
were sterilized by immersion into 70% ethanol (v/v in distilled water) for 30 minutes, 164 
followed by washing with sterile PBS. Scaffolds were then  cannulated with a 24G 165 
cannula (BD Insyte™) under a dissection microscope (Wild Heerbrugg M3Z). In this 166 
study, varying cell combinations were seeded onto and within the synthetic scaffolds. 167 
These included; HDMECs seeded into the channels, a combination of HDMECs and 168 
HDFs seeded within the channels and finally HDMECs seeded within the channels 169 
and HDFs seeded on the outside surface of the channels. To ensure cells attached 170 
uniformly to the artificial channels seeding was performed using a two-stage process.  171 
First, 0.5 × 10
6
 HDMECs (per scaffold) were resuspended in 0.25ml of EC growth 172 
medium MV. Using a 1ml syringe the cell suspension was injected into the scaffold 173 
through the cannula, submerged in media and kept overnight in an incubator at 37 ¡C 174 
 and 5% CO2. The constructs were then turned over and a second suspension of 0.5 × 175 
10
6
 HDMECs was seeded and left overnight. For the introduction of HDFs into the 176 
channels, HDMECs were firstly allowed to attach to the scaffolds for a minimum of 3 177 
hours before injecting 0.5 × 10
6 
HDFs and repeating this process following the second 178 
injection of HDMECs. For the introduction of HDFs onto the outside surface of the 179 
channels 0.5 × 10
6 
HDFs were pipetted over the outer surface of the scaffolds 180 
immediately after the seeding of the HDMECs. The scaffolds were placed in an 181 
incubator for up to 2 hours at 37 ¡C and 5% CO2 without being submerged in media 182 
to allow attachment of the HDFs. The scaffolds were then subsequently submerged in 183 
media overnight before repeating the process. 184 
 185 
Outgrowth of endothelial cells from biodegradable scaffolds into an extracellular 186 
matrix.  Scaffolds that had been recellularized and cultured at 37¡C and 5% CO2 for 7 187 
days were taken and the channels were pierced with a sterile 21G hypodermic needle 188 
(Terumo, MediSupplies, UK) to introduce small holes into the scaffold to allow cell 189 
migration out of the scaffold. Collagen gels (2 mg/ml) were prepared by adding 200 190 
µl rat tail collagen type I (3 mg/ml, Gibco, Life technologies, UK) to 100 µl of 191 
concentrated MEM solution (Gibco, Life Technologies, UK) and vascular endothelial 192 
growth factor (VEGF) to a final concentration of 10 ng/ml. The collagen solution 193 
(~50 µl) was then pipetted into the wells formed by the channels and allowed to set at 194 
37¡C for 15 min. The scaffolds were then submerged in media and cultured for a 195 
further 7 days, changing the media every 3 days. 196 
 197 
Immunohistochemistry Samples were fixed for 2 hours in 4% paraformaldehyde 198 
(PFA) w/v in HBSS with Ca
2+
 and Mg
2+
 before dehydrating using graded alcohol 199 
 washes and embedding in paraffin wax. 6 µm sections were cut and mounted on 200 
slides and stained with Hematoxylin and Eosin (H&E) (Sigma Aldrich). 201 
 202 
Immunofluorescence staining. Immunofluorescence staining was performed as 203 
described previously [Correa de Sampaio et al., 2012].  Briefly, samples were fixed in 204 
4% PFA (w/v) in HBSS with Ca
2+
 and Mg
2+
 for 30 minutes.  Samples were then 205 
quenched with 100 mM glycine, washed once with PBS and then blocked for 1 h with 206 
1% (w/v) bovine serum albumin (BSA) in PBS at room temperature (RT).  Separate 207 
samples were then incubated with mouse monoclonal anti-human CD31 (1:20 in 1% 208 
(w/v) BSA, Dako, UK) and mouse monoclonal anti-human VE cadherin (CD144) 209 
(1:50 in 1% (w/v) BSA, BD Biosciences) at RT overnight..  The scaffolds were 210 
subsequently washed for 2 h in 1% BSA (w/v) in PBS with 0.1% Tween (v/v), 211 
followed by incubation with Alexa Fluor™ 546 nm goat anti-mouse secondary 212 
antibody (1:200 in 1% (w/v) BSA) (Life technologies) for 2 h at RT before 213 
counterstaining with the nuclear stain DAPI (1:1000 in 1% (w/v) BSA).  Finally the 214 
scaffolds were washed with 1% BSA (w/v) in PBS with 1% Tween (v/v) for at least 8 215 
h, after which the samples were imaged using a Zeiss LSM 510 confocal microscope 216 
(Zeiss, UK) to observe cellular organization.  217 
 218 
Perfusion with FITC-lectin To visualize potential vessel formation, the scaffolds were 219 
perfused with 100 µl of FITC labelled tomato lectin (Vector Laboratories) at a rate of 220 
40 µl/min, controlled using a syringe pump (Genie Plus, Kent Scientific, Connecticut, 221 
USA).The scaffolds were then fixed in 4% PFA (w/v) in HBSS with Ca
2+
 and Mg
2+
 222 
for 30 minutes and subsequently immunostained for CD31 as described above.  223 
 224 
  225 
Results  226 
The formation of a continuous endothelial cell monolayer within the pseudovascular 227 
net lumen requires the support of fibroblasts 228 
In order for the electrospun pseudovascular net ( shown in Fig 1A) to act as a model 229 
vascular structure that can support neovascularization within biological structures, 230 
optimization of seeding and growth of an endothelial monolayer within the scaffold 231 
lumen was performed. Initially HDMEC were injected ( by perfusing the nets by 232 
inserting a syringe as shown in Fig 1B )  at high density within the lumen alone and 233 
allowed to adhere to the upper and lower surfaces.  After 7 days culture cell coverage 234 
was investigated using hematoxylin and eosin staining of the pseudovascular net in 235 
cross-section (Fig 2). Although HDMEC could be detected, coverage was not 236 
continuous (Fig. 2 A ÐC). Mesenchymal cells, including pericytes and fibroblasts, 237 
have been shown to support endothelial function in in vitro models, mimicking 238 
perivascular cells [Kirkpatrick et al., 2011]. To determine if HDFs can augment 239 
HDMEC adhesion and survival within the pseudovascular net, HDFs were first 240 
seeded within the lumen with the HDMECs as in other vascular models this can result 241 
in a self-organising system replicating endothelial-pericyte architecture [Kunz-242 
Schughart et al., 2006; Hurley et al., 2010]. This resulted in continuous cellular 243 
coverage of the inside of the lumen (Fig. 2 D-F). As some of the signalling pathways 244 
known to regulate endothelial barrier function are also soluble growth factors, we also 245 
seeded HDFs on the outside of the pseudovascular net and HDMECs on the inside of 246 
the lumen, physically separating the cells. On H&E staining, increased cell coverage 247 
of the lumen was seen, although this did not appear as continuous as the seeding both 248 
HDMECs and HDFs within the lumen (Fig 2 G-I).  249 
 To further characterize the EC coverage within the lumen of the pseudovascular net, 250 
the net was sectioned to reveal the upper curved surface and the lower flat surface 251 
before staining with CD31 and DAPI and confocal imaging. In nets seeded with 252 
HDMECs alone, CD31 staining lacked continuity and the ECs had a rounded 253 
appearance, with little to no evidence of CD31 at cell-cell junctions, especially on the 254 
curved surface (Fig 3 A-B).  Although H&E staining showed a continuous cell layer 255 
with both HDFs and HDMECs were seeded within the lumen, the CD31 staining did 256 
not show continuous endothelial coverage.  However, unlike surfaces with ECs alone, 257 
patches of confluent ECs were observed with discernable cell-cell junction staining of 258 
CD31 that appeared to be partially detracted from the HDFs cells on the 259 
pseudovacular net, suggesting poor adhesion (Fig 3 C-D).  In contrast, the 260 
combination of HDFs on the external surface and HDMECs on the internal surface 261 
generated a continuous endothelial monolayer with a characteristic ÔcobblestoneÕ 262 
appearance and clear cell-cell junction staining of CD31, particularly on the curved 263 
surface (Fig 3 E-F).  Furthermore, staining for the endothelial adherens junction 264 
protein VE-Cadherin confirmed the establishment of a confluent monolayer on the 265 
inside of the lumen when HDFs were cultured on the outside (Fig 4 A-B). 266 
 267 
Endothelial cells maintain the capacity to migrate out of the pseudovascular net to 268 
form new perfusable vascular structures within a biological matrix 269 
After establishing the HDMECs could form a continuous monolayer of cell within the 270 
lumen of the pseudovascular net, we next aimed to determine if these  had the 271 
capacity to form new vascular structures within a biological matrix, as this would be 272 
required if the artificial vascular structure is to have the ability to integrate with 273 
engineered tissues or biological material in the future. Initial studies indicated that 274 
 HDMECs would not be able degrade the electrospun mat or invade through it in a 275 
timely manner for this to occur. Accordingly, the pseudovascular net was punctured 276 
providing discreet exit points for the HDMECs. The well-shaped region within the 277 
netÕs hexagon pattern was then filled with collagen-I gel containing VEGF to promote 278 
migration of the ECs from within the net into the gel (Fig 5A). After 7 days of culture 279 
a CD31 positive network was found extending throughout this collagen-I gel  with the 280 
appearance of a crude vascular network (Fig 5B) surrounded by HDFs that had also 281 
migrated into the gel.   282 
We then aimed to determine if the new vasculature could be perfused via the 283 
pseudovascular net by injection of FITC-Lectin, commonly used in vivo to investigate 284 
vascular function [Thurston et al., 1998; Ezaki et al., 2001; Mazzetti et al., 2004]. 285 
Confocal imaging showed significant overlap between CD31 and FITC-Lectin 286 
indicating perfusion had occurred (Fig 5C).  It is important to note that these 287 
experiments were repeated 5 times with at least 6 replicates per experiment and vessel 288 
formation was found in around 50% of samples. 289 
These structures generated in the pseudovascular nets were apparently random and 290 
looked more like large sinusoids/lymphoid structures than blood vessels.  In width 291 
they ranged from 10µm up to structures which at their widest were closer to 80µm. 292 
There was no obvious pattern. They extended partially throughout the collagen 293 
/VEGF gel (spanning approximately 1cm from the peripheral vascular channel in all 294 
directions) within the 7 days of culture. 295 
 296 
Discussion 297 
The aim of this study was to develop a controllable 3D in vitro model of vascular 298 
structures to study the factors affecting angiogenesis and vascular biology.  The 299 
 ultimate aim of this work is to translate the use of such vascular networks to the clinic 300 
in order to assist in the ÒtakeÓ of TE materials that lack intrinsic vasculature.   301 
For many years it has been recognized that while it is possible to produce human 3D 302 
TE constructs in the laboratory, unless they are very thin epithelial structures they can 303 
be lost upon transplantation due to delays in neovascularization [Griffith et al., 2005].  304 
Introducing a vascular network into a TE construct is a major challenge which only a 305 
few groups are tackling.  In an attempt to understand the fundamental principles 306 
behind the induction of angiogenesis, development of 3D models investigating the 307 
interactions between different cell types have progressed [Montesano et al. 1993; 308 
Donovan et al., 2001; Santos et al., 2008].  Other studies have looked at the influence 309 
of fluid flow on EC survival and sprouting [Moll et al., 2013; Vukadinovic-Nikolic et 310 
al., 2014].  However, we are unaware of any models that have the ability to combine 311 
different cell combinations and fluid flow to investigate the induction of early stage 312 
blood vessel formation for TE applications. 313 
This work represents a significant step towards this goal.  Our aim was to develop a 314 
simple synthetic pseudo-vascular network which could be recellularized to form an 315 
interconnected monolayer of ECs.  A promising or successful structure was viewed as 316 
one which could demonstrate evidence of new vessel formation, sprouting outwardly 317 
from these re-endothelialized channels.  The main finding of this study was the 318 
production of tubular architectures emerging from the pseudo-vasculature in response 319 
to the proangiogenic mitogen VEGF.   320 
This study shows that lining of the synthetic vasculature with HDMECs was not very 321 
successful when these cells were introduced on their own.  Their ability to adhere and 322 
form a continuous lining was much improved by the addition of HDFs, particularly 323 
when added to the outer layer of the synthetic channels.  In summary endothelial 324 
 cover was relatively poor with HDMECs alone, better with the inclusion of HDFs 325 
inside the lumen together with HDMECs but best of all with HMDEC inside and 326 
HDFs outside the lumen.   In other recent studies we show that fibroblasts themselves 327 
are not able to penetrate through a nanofibrous PHBV electrospun layer even after 328 
two weeks of culture [ Bye et al., 2013 and 2014]. 329 
Accordingly we speculate that this arrangement, HDMECs inside the channels with 330 
HDFs outside, provides the opportunity for cross talk and ÒreassuranceÓ of the 331 
HDMECs by the fibroblasts as found in other studies [Dietrich and Lelkes, 2006; 332 
Kunz-Schughart et al., 2006; Hughes, 2008; Kirkpatrick et al., 2011].  It is likely that 333 
both are producing soluble and ECM factors, however this was not investigated in this 334 
particular study.   335 
After the successful re-endothelialization of the synthetic channels we were keen to 336 
explore whether new vessels would sprout from these channels in response to 337 
proangiogeneic stimuli; the criteria that had been originally selected as the definition 338 
of a successful system.  Results showed that placing VEGF loaded collagen gels onto 339 
the scaffolds caused HDMEC outgrowth to occur from within the channels into the 340 
collagen gel showing that the engineered vasculature maintained its capacity for 341 
angiogenesis.  Furthermore the HDMECs appeared to have formed perfusable tubules 342 
( determined by connecting these nets to a syringe pump and perfusing at 40 µl/min) 343 
within the gel.  However, these tubules did not look like ÔnormalÕ blood vessels and 344 
were arguably closer to angiomas.  There are many studies that show that VEGF on 345 
its own will direct migration of ECs but this commonly results in the formation of 346 
large and leaky vessels [Jain and Munn, 2000; Tomanek, 2002; Thurston, 2002].  It is 347 
suspected that this is the case in this particular study.  It is also important to note that 348 
these results were found in around 50% of experiments, highlighting the need for 349 
 further optimization.  However we emphasize that this is to the best of our knowledge 350 
the first demonstration of endothelial tubule formation in 3D from a synthetic 351 
vascular network.  The rate of perfusion and detailed flow effects were not  examined 352 
in this study (perfusion was at a fixed rate of 40 µl/min in these experiments) but this 353 
should now be possible using these synthetic pseudo-vascular networks.  Similarly we 354 
do not know what role the added fibroblasts play in the formation of these structures. 355 
In summary we previously reported the production of an EC lined synthetic pseudo-356 
vascular network [Ortega et al., 2015].  This study has developed this work a 357 
significant step further in showing the production of perfusable tubular sprouts 358 
emanating from the HDMEC lined networks in response to the proangiogenic 359 
mitogen VEGF.  This system will now lend itself to investigations of perfusion flow, 360 
the response of the cells to combinations of angiogenic mitogens and to the 361 
examination of the nature of the cross talk between the HDMECs and HDFs.  It will 362 
also be important to examine the response to these cell-seeded constructs implanted in 363 
an animal model in the future. Overall these results indicate promising steps towards 364 
the development of an in vitro platform in which to study angiogenesis and vascular 365 
biology for a range of applications.  366 
 367 
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List of Abbreviations 377 
 378 
HDMECs   Human dermal microvascular endothelial cells 379 
HDFs    Human dermal fibroblasts 380 
EC    Endothelial cell 381 
TE    Tissue engineered 382 
ECM    Extra cellular matrix 383 
VEGF    Vascular endothelial growth factor 384 
PHBV   Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) 385 
DCM     Dichloromethane 386 
EDTA    Ethylenediaminetetraacetic acid 387 
H&E     Hematoxylin and Eosin 388 
RT     Room temperature 389 
PFA   Paraformaldehyde 390 
FFPE                           Formalin fixed paraffin embedded 391 
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 Figure Legends 490 
 491 
Figure 1.  Appearance of pseudovascular net and diagram of its perfusion. A shows 492 
the appearance of one of the pseudovascular nets which had the overall dimensions of 493 
2cm x 4cm.  B shows that the pseudovascular net is designed to be  cannulated with a 494 
needle and perfused.  For detailed description of the production of the pseudovascular 495 
net, please see Ortega et al, 2015.  496 
 497 
Figure 2. Immunohistochemical staining of human dermal fibroblasts and human 498 
dermal microvascular endothelial cells on the surfaces of the pseudovascular net 499 
A Ð C. FFPE cross sections through a vascular scaffold where HDMECs were seeded 500 
on the inside of the scaffold lumen, stained with H&E and imaged 4, 10 and 20 × 501 
magnification respectively. (For a detailed description of the production of these 502 
scaffolds please see Ortega et al 2015 ).Scale bar shows 100 µM. D Ð F. As in A Ð C, 503 
but showing scaffolds with HDMECs and HDFs seeded within the scaffold lumen. G 504 
Ð I. As in A Ð C but with HDMECs seeded inside and HDFs seeded outside the 505 
vascular scaffold. 506 
 507 
Figure 3. Confluent endothelial monolayers within the pseudovascular netÕs channels 508 
are formed with support of human dermal fibroblasts. 509 
Pseudovascular nets were sectioned parallel to the lower surface of the channel 510 
(indicated by cartoon above images) and both surfaces were immunostained with anti-511 
CD31 (HDMECs, red) and DAPI (nuclei, blue) before images were taken by confocal 512 
microscopy and z-stacked images compressed to generate an image of the whole 513 
surface. Scale bar = 100 µM. A and B. Upper and lower inner surfaces seeded with 514 
 HDMECs alone. C and D. Upper and lower inner surfaces seeded with HDMECs and 515 
HDFs seeded inside the channel of the vascular net. E and F. Upper and lower inner 516 
surfaces seeded with HDMECs inside the channel and HDFs seeded outside the 517 
channel of the pseudovascular net. 518 
 519 
Figure 4. Endothelial cells on the inside surface of the pseudovascular net have VE-520 
Cadherin positive adherens junctions. Pseudovascular nets were seeded with 521 
HDMECs inside the channel and HDFs outside the channels and sectioned as 522 
described in Fig 3. Sections were immunostained with anti-VE-Cadherin (red) and 523 
DAPI (nuclei, blue) before images were taken by confocal microscopy. Z-stacks of 524 
images were compressed to generate an image of the whole surface. A ÐScale bar = 525 
100 µM. B - Scale bar = 20 µM. 526 
 527 
Figure 5. Human dermal endothelial cells exit the pseudovascular net to form a 528 
perfusable network within VEGFA loaded collagen-I gels. A. Diagram showing the 529 
process of making holes in a pseudovascular net that has been pre-seeded internally 530 
with HDMECs, and externally with HDFs. After 7 days culture, holes are made on the 531 
inner side of the netÕs artificial vascular channels facing into the hexagonal well using 532 
a 21 gauge needle. The hexagonal area is then filled with collagen-I containing 533 
VEGFA and allowed to set before submerging in medium for a further 7 days to allow 534 
growth of cells from the net into the collagen gel. B. 3D confocal projection of CD31 535 
positive structures within the collagen-I gel from the centre of the hexagonal well. C. 536 
Confocal images of nuclei (blue), Lectin-FITC (green) and CD31 (red) and merged 537 
image of all three channels of the collagen-I gel within the centre of the hexagonal 538 
well after perfusion of the pseudovascular net with Lectin-FITC. Scale bar is 100 µm. 539 
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